2015 saw tangible progress in the field of neuroregenerative medicine. The first PD patients to receive their cell transplants underwent surgery in Cambridge in the TransEuro study led by Professor Roger Barker, and part-funded by CPT. 

Advances in stem cell therapies continue to progress – a study, also funded by CPT, has determined the best candidate cells to undergo future transplantation into PD patients. This study has also addressed immunological resistance and provided a clear framework for all trials in the future using Induced Pluripotent Stem Cells (IPS), and eventually, pluripotent stem cells derived from an individual patient's own skin cells.

  • For further reading in this field of research, click here.

Four years after our first Linked Clinical Trials meeting, we are so pleased to be able to report that a number of trials are underway or nearly underway, for treatments prioritised by an elite committee of international Parkinson's experts. These are drugs developed to treat other conditions so are already proven safe, but importantly we all believe they each show the potential to slow down or even stop Parkinson’s.

  • Liraglutide (prioritised in 2012 - funding has now been secured and we are awaiting a final decision about drug/placebo requirements)
  • Ambroxol (prioritised in 2014 – funding is now secured and the trial is due to start in 2016)
  • EPI-589 (prioritised in 2013 – funding has been given by Edison Pharmaceuticals and the trial is due to start in 2016)
  • Simvastatin (prioritised in 2012 – the trial is now underway) 

For further information about these trials click here.

  • N-acetyl cysteine (prioritised in 2014 – the trial is being designed and funding is still required)
  • Lixisenatide (prioritised in 2012 – agreement of funding is near completion, the drug and placebo have been provided by Sanofi)
  • BG12 (prioritised 2015 – early discussions are underway to develop this trial and funding is still required)
  • UDCA (prioritised 2015 – the trial has been designed and funding is still required)
  • Axitinib (prioritised 2015 – early discussions are underway to develop this trial and funding is required) This drug type has shown promising potential to be neuroprotective and neurorestorative and we are keen to progress trials using this class of drugs. Click here for more information.